• Follow Us
CDI Labs LogoCDI Labs Company Logo
  • LAB SERVICES
      • Service Platforms
      • OVERVIEW
      • HuProt™ Services
      • VirD™ Services
      • VirScan® Services*
      • HuScan® Services*
      • MouseScan™ Services*
      • Tech Access ProgramCustom PhIP-Seq Libraries*
      • Autoantibody Seromics Services
      • OVERVIEW
      • Biomarker Discovery
      • Patient Stratification
      • Patient Response / Adverse Reaction Prediction
      • Diagnostic Development
      • Vaccine Development and Safety
      • Viral Exposure Profiling
      • Target ID Services
      • OVERVIEW
      • Protein-Protein Interactions
      • Protein-Nucleic Acid Interactions
      • Target Deconvolution / Target Discovery
      • Antibody Specificity Validation
      • Post-translational Modification Specificity Testing
      • Chemically Induced Proximity (CIP)
      • Disease Areas
      • OVERVIEW
      • Autoimmune Disease
      • Oncology
      • Neurological Disease
      • Infectious Disease
      • Genetic Disease
      • * Provided exclusively by CDI Labs Canada.
  • SPECIALIZED CRO SERVICES
      • Specialized CRO Services
      • OVERVIEW
      • Antibody Development
      • Antibody Pairs
      • Protein Production
      • Cell Therapy Immunogenicity Testing
      • CRISPR-Cas9 Immunogenicity Testing
      • Post-translational Modification Specificity Profiling
      • Diagnostic Development
  • PROTEOMICS TECHNOLOGIES
      • HuProt™ MicroarrayContains 21,000+ Full-length Human Proteins
      • VirD™ Membrane ProteinContains429 Membrane Proteins and Isoforms
      • VirScan® PhIP-Seq*Detect antibodies against 68,000+ Viral Protein Sequences
      • HuScan® PhIP-Seq*Detect antibodies against 48,921 Human Proteins and Isoforms
      • MouseScan™ PhIP-Seq* Detect antibodies against 50,135 Murine Proteins and Isoforms
      • * Provided exclusively by CDI Labs Canada.
  • BIOINFORMATICS
      • Bioinformatics
      • OVERVIEW
  • RESOURCES
      • Resources
      • Library Content
      • Publications
      • Videos and Webinars
      • FAQs
  • NEWS  &  EVENTS
      • Blogs
      • Events
      • News
  • COMPANY
      • About Us
      • Leadership
      • Meet CDI Labs
      • Tech Access ProgramCustom PhIP-Seq Libraries*
      • Customer Testimonials
      • Contact Us
      • Sign-up for Our eNews
      • Privacy Policy
  • CONTACT US

You are now leaving the CDI Labs U.S. website and will be directed to the CDI Labs Canada website.

< Older Newer >
Download PDF
  • Share

Wednesday, Mar 08 2018

CDI Labs Collaborates on Discovery of New Biomarkers for Zika Infection

MAYAGUEZ, Puerto Rico and BALTIMORE, March 8, 2018 - Newly published research in Molecular & Cellular Proteomics* describes a biomarker panel based on patient IgM antibodies that can differentiate between Zika and Dengue virus infection for a prolonged period after initial exposure. CDI's expertise in protein microarrays was instrumental in the development of this assay.


Zika virus (ZIKV) and dengue virus (DENV) are closely related flaviviruses that cause widespread, acute febrile illnesses. Being able to differentiate between ZIKV and DENV over a longer period of time is critical because ZIKV is known to cause of microcephaly and severe brain abnormalities in utero and has been linked to other birth defects while DENV has not. The current approved RT-PCR tests can only detect ZIKV infection specifically within seven days from the onset of any symptom. As the infection progresses, clinicians or diagnosticians must rely on IgM-based ELISA assays which cannot reliably distinguish ZIKV infection from DENV infection. Therefore, development of a serological biomarker(s) that can detect and discriminate between the two infections is very important.


The participants in this study included labs from Johns Hopkins (Drs. Heng Zhu and Jiang Qian), UPenn, Florida State, along with a great deal of work from the labs of Drs. Jorge L. Muñoz-Jordan and Freddy A. Medina at the Centers for Disease Control and Prevention, Dengue Branch


"CDI is glad it could help on this study. Being based in Puerto Rico, the Zika problem is a personal one for us," said Scott Paschke, CDI Vice President. "Working on this important problem alongside these top scientists was indeed a pleasure and we hope it leads to large scale adoption of utilizing this panel for accurate diagnosis of Zika, as well as development of additional tests and treatments."


*Guang Song, Hee-Sool Rho, Jianbo Pan, Pedro Ramos, Ki-Jun Yoon, Freddy A. Medina, Emily M. Lee, Daniel Eichinger, Guo-li Ming, Jorge L. Muñoz-Jordan, Hengli Tang, Ignacio Pino, Hongjun Song, Jiang Qian, Heng Zhu (November 2017) Multiplexed biomarker panels discriminate Zika and Dengue virus infection in humans. Mol Cell Proteomics mcp.RA117.000310. First published November 15, 2017, doi: 10.1074/mcp.RA117.000310.



About CDI - A privately-owned biotechnology corporation, CDI Labs focuses on protein/antibody microarray design, production, and custom assay services. CDI's flagship - HuProt™ - is the most comprehensive human proteome microarray in the industry, allowing thousands of protein interactions to be profiled in parallel. HuProt enables R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. The HuProt™ arrays are available for purchase by labs with in-house microarray scanning capability. Alternatively, CDI's Discovery Services division offers contract assay design, research, bioinformatics and custom-configured microarray production on a per-project basis. CDI's Fast-MAb® hybridoma development service addresses the urgent need for monoclonal antibodies with unprecedented specificity for research, diagnostic or therapeutic targets. Fast-MAb® antibodies are evaluated for specificity on HuProt arrays. The Company exports products worldwide and is expanding its clientele base and academic and industrial collaborations.


For more information, visit cdi-lab.com




Media Contact:

Scott Paschke, Vice President

CDI Laboratories Inc.

518-534-2881 (direct)

[email protected]

  • CDI LABSLinkedin Feed
CDI Labs Footer LogoCDI Labs Company Footer Logo

Become part of the CDI Labs community

Sign up to receive emails on our latest news and updates.

Your First Name
Your Last Name
Your Work Email

Please enter ONLY your work email address.

Sign Up Submit Button

PLATFORMS

  • HuProt™ Proteome Microarray
  • VirD™ Membrane Protein Array
  • VirScan® Viral PhIP-Seq*
  • HuScan® Human PhIP-Seq*
  • MouseScan™ Murine PhIP-Seq*
  • * Provided exclusively by CDI Labs Canada.

SERVICES

  • HuProt™ Services
  • VirD™ Services
  • VirScan® Services*
  • HuScan® Services*
  • MouseScan™ Services*
  • Antibody Development
  • Autoantibody Seromics Overview
  • Target ID Overview
  • Disease Areas Overview
  • Specialized CRO Overview
  • Bioinformatics Overview
  • * Provided exclusively by CDI Labs Canada.

COMPANY

  • Resources
  • Library Content
  • Publications
  • FAQs
  • Videos and Webinars
  • Blogs
  • Events
  • News
  • Sign-up for Our eNews
  • About Us
  • Leadership

CONTACT

  • Email: [email protected]
  • Tel: +1 844-539-6296
  • CONTACT US
  • General Inquiries
  • [email protected]
  • Tel: +1 510 858-2855
  • Technical Support
  • [email protected]
  • Tel: +1 844 539-6296
  • Mailing Address
  • PO. Box 569
  • Mayagüez. PR 00681-0569
  • USA
  • CDI Labs - Mayagüez
  • 12 W Mendez Vigo Avenue
  • 2nd Floor
  • Mayagüez, PR 00680
  • USA
  • Tel: +1 939-280-5293
  • DIRECTIONS
  • CDI Labs - Baltimore
  • 1 N. Haven Street
  • Suite B001
  • Baltimore, MD 21224
  • USA
  • Tel: +1 844-539-6296
  • DIRECTIONS
  • CDI Labs Canada - Toronto
  • MaRS Centre - West Tower
  • 661 University Ave
  • Suite 1300
  • Toronto, ON
  • CANADA M5G 0B7
  • Tel: +1 647-243-5289
  • DIRECTIONS
  • Follow Us

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

© 2025 CDI Labs. All rights reserved.

  • Privacy Policy
  • |
  • Cookie Policy
  • |
  • Terms of Use - Web
  • |
  • Terms & Conditions - Sales
  • |
  • Terms & Conditions - Services